Angiogenesis in multiple myeloma

Seminars in Oncology

Volumn 28, Issue 6, 2001, Pages 560-564

  Rajkumar, S V ^a   Kyle, R A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; CD34 ANTIGEN; M PROTEIN; PARAPROTEIN; THALIDOMIDE; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; BONE MARROW; CANCER GROWTH; CANCER RESEARCH; CLINICAL TRIAL; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

EID: 0035210921     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90024-7     Document Type: Article

References (29)

1. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
2. Tumour angiogenesis and prognosis
3. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
4. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
5. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
6. Cancer statistics, 2000
7. Multiple myeloma
8. Monoclonal gammopathies of undetermined significance
9. "Benign" monoclonal gammopathy - After 20 to 35 years of follow-up
10. Staging, kinetics, and prognosis of multiple myeloma
11. Bone marrow angiogenesis and progression in multiple myeloma
12. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies
13. Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation
14. Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis
15. Tumour angiogenesis
16. Computerized image analysis in the assessment of bone marrow angiogenesis in multiple myeloma
17. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
18. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), active myeloma (MM), relapsed myeloma (RMM) and primary amyloidosis (AL)
19. Prognostic value of bone marrow angiogenesis in multiple myeloma
20. Bone marrow (BM) angiogenesis in multiple myeloma (MM): Effect of therapy and prognostic value
21. Angiostatin induces and sustains dormancy of human primary tumors in mice
22. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
23. Antitumor activity of thalidomide in refractory multiple myeloma
24. Thalidomide in the treatment of relapsed and refractory myeloma
25. Thalidomide in the treatment of relapsed multiple myeloma
26. A phase II trial of thalidomide in the treatment of relapsed multiple myeloma (MM) with laboratory correlative studies
27. Thalidomide with dexamethasone for resistant multiple myeloma
28. Single course D.T. PACE anti-angiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma (MM)
29. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?